Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
eqs_en 
0 27.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 27.04.23
EQS-Adhoc: GN Store Nord A/S: GN Store Nord delivered 7% organic revenue growth driven by strong market share gains. Full year guidance upgraded: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: GN Store Nord delivered 7% organic revenue growth driven by strong market share gains. Full year guidance upgraded
EQS-Adhoc: GN Store Nord A/S: GN Store Nord delivered 7% organic revenue growth driven by strong market share gains. Full year guidance upgraded
eqs_en 
0 26.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 26.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 25.04.23
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
eqs_en 
0 25.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 24.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 20.04.23
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
eqs_en 
0 20.04.23
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed
eqs_en 
0 20.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 19.04.23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
eqs_en 
0 19.04.23
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
eqs_en 
0 18.04.23
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
eqs_en 
0 18.04.23
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
eqs_en 
0 18.04.23
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
eqs_en 
0 18.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 18.04.23
EQS-News: Newron announces AGM 2023 results  : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces AGM 2023 results  
EQS-News: Newron announces AGM 2023 results  
eqs_en 
0 18.04.23
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
eqs_en 
0 18.04.23
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed: https://assets2.sharewise.com/attachment/file/24054/375px-Dr%C3%A4ger_Logo.svg.png
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
eqs_en 
0 17.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 17.04.23
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
eqs_en 
0 16.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 14.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 13.04.23
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flowhttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow
eqs_en 
0 13.04.23